Patent application number | Description | Published |
20110189178 | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions - The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes. | 08-04-2011 |
20130156754 | Optimized Fc Variants and Methods For Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 06-20-2013 |
20130156758 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 06-20-2013 |
20130171095 | Method for Purifying Antibodies - The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains. | 07-04-2013 |
20130177553 | Novel Compositions and Methods for Treating IgE-Mediated Disorders - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 07-11-2013 |
20130209457 | Optimized Fc Variants - The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds FcγRIIb with increased binding affinity compared to a human parent Fc region. | 08-15-2013 |
20130243762 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 09-19-2013 |
20130261289 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 10-03-2013 |
20130273043 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 10-17-2013 |
20130302315 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 11-14-2013 |
20140073768 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 03-13-2014 |
20140161790 | ENGINEERED IMMUNOGLOBULINS WITH EXTENDED IN VIVO HALF-LIFE - The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes. | 06-12-2014 |
20140212435 | RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 07-31-2014 |
20140212436 | RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES - The present invention relates to rapid clearance molecules that bind target antigens and FcγRIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions. | 07-31-2014 |
20140288275 | NOVEL HETERODIMERIC PROTEINS - The invention provides novel heterodimeric proteins including heterodimeric antibodies. | 09-25-2014 |
20140294759 | TARGETING REGULATORY T CELLS WITH HETERODIMERIC PROTEINS - The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells. | 10-02-2014 |
20140294823 | HETERODIMERIC PROTEINS - The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings. | 10-02-2014 |
20140294835 | NOVEL HETERODIMERIC PROTEINS - The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different. | 10-02-2014 |
20140322217 | NOVEL HETERODIMERIC PROTEINS - The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different. | 10-30-2014 |
20140356381 | METHODS OF PURIFYING HETERODIMERIC PROTEINS USING IMMUNOGLOBULIN CLASS SWITCHING - The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings. | 12-04-2014 |
20140363426 | HETERODIMERIC PROTEINS - In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain. | 12-11-2014 |
20140370021 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 12-18-2014 |
20140377270 | OPTIMIZED ANTIBODY VARIABLE REGIONS - The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 12-25-2014 |
20150030592 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-29-2015 |
20150031862 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-29-2015 |
20150071948 | NOVEL IMMUNOGLOBULIN VARIANTS - The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same. | 03-12-2015 |
20150079082 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 03-19-2015 |